Coherus Oncology (NASDAQ:CHRS) Announces Earnings Results

Coherus Oncology (NASDAQ:CHRS) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01, FiscalAI reports. The firm had revenue of $11.57 million during the quarter, compared to analyst estimates of $13.41 million.

Coherus Oncology Stock Performance

Shares of CHRS traded down $0.15 during mid-day trading on Friday, hitting $1.34. The stock had a trading volume of 2,920,956 shares, compared to its average volume of 1,037,423. The company has a quick ratio of 1.43, a current ratio of 1.44 and a debt-to-equity ratio of 0.31. The company has a market cap of $155.74 million, a PE ratio of 1.01 and a beta of 0.96. Coherus Oncology has a fifty-two week low of $0.70 and a fifty-two week high of $2.43. The company’s fifty day simple moving average is $1.55 and its two-hundred day simple moving average is $1.13.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Coherus Oncology in a report on Wednesday, October 8th. Wall Street Zen raised Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Maxim Group upgraded Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Thursday, September 4th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $4.51.

Institutional Trading of Coherus Oncology

A number of institutional investors and hedge funds have recently modified their holdings of CHRS. Corient Private Wealth LLC grew its position in shares of Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 10,000 shares during the last quarter. Jane Street Group LLC acquired a new position in Coherus Oncology in the second quarter valued at approximately $46,000. XTX Topco Ltd grew its holdings in shares of Coherus Oncology by 65.3% during the second quarter. XTX Topco Ltd now owns 91,739 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 36,257 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Coherus Oncology by 52,980.1% during the 1st quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 196,556 shares during the period. Finally, Invesco Ltd. raised its position in shares of Coherus Oncology by 11.5% during the 2nd quarter. Invesco Ltd. now owns 208,271 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 21,550 shares during the period. 72.82% of the stock is owned by institutional investors and hedge funds.

About Coherus Oncology

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.